
|Articles|November 1, 2003
ENROLLEMENT COMPLETED
Maxim pharmaceuticals has completed enrollment for the confirmatory Phase 3 trial of its lead drug candidate Ceplene? (histamine dihydrochloride) in combination with interleukin-2 (IL-2) for the treatment of advanced malignant melanoma patients with liver metastases.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











